SQUAWK/NEWS
Account
Theme
Account
Menu
Live News MACRO FLASH L impact

Phase 2 Trial Finds JAK Inhibitor Safely Reduces Immune

A Phase 2 clinical trial published in Cell Reports Medicine found that a JAK inhibitor safely reduces immune activity in people with Down syndrome.

Related stories